Viamet Pharmaceuticals (United States)

Recent papers from Viamet Pharmaceuticals (United States)

1. A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal CandidiasisClinical Infectious Diseases · 2020
2. The novel fungal CYP51 inhibitor VT-1598 displays classic dose-dependent antifungal activity in murine models of invasive aspergillosisMedical Mycology · 2019
3. Impact of the Major Candida glabrata Triazole Resistance Determinants on the Activity of the Novel Investigational Tetrazoles VT-1598 and VT-1161Antimicrobial Agents and Chemotherapy · 2019
4. In Vitro Activities of the Novel Investigational Tetrazoles VT-1161 and VT-1598 Compared to the Triazole Antifungals against Azole-Resistant Strains and Clinical Isolates of Candida albicansAntimicrobial Agents and Chemotherapy · 2019
5. The Fungal Cyp51-Specific Inhibitor VT-1598 Demonstrates In Vitro and In Vivo Activity against Candida aurisAntimicrobial Agents and Chemotherapy · 2018
6. The novel fungal CYP51 inhibitor VT-1598 is efficacious alone and in combination with liposomal amphotericin B in a murine model of cryptococcal meningitisJournal of Antimicrobial Chemotherapy · 2018
7. VT-1598 inhibits the in vitro growth of mucosal Candida strains and protects against fluconazole-susceptible and -resistant oral candidiasis in IL-17 signalling-deficient miceJournal of Antimicrobial Chemotherapy · 2018
8. The Novel Fungal Cyp51 Inhibitor VT-1598 Is Efficacious in Experimental Models of Central Nervous System Coccidioidomycosis Caused by Coccidioides posadasii and Coccidioides immitisAntimicrobial Agents and Chemotherapy · 2018
9. Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizusJournal of Antimicrobial Chemotherapy · 2017
10. VT-1161 protects mice against oropharyngeal candidiasis caused by fluconazole-susceptible and -resistant Candida albicansJournal of Antimicrobial Chemotherapy · 2017
11. Prophylactic Treatment with VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus InfectionAntimicrobial Agents and Chemotherapy · 2017
12. The Tetrazole VT-1161 Is a Potent Inhibitor of Trichophyton rubrum through Its Inhibition of T. rubrum CYP51Antimicrobial Agents and Chemotherapy · 2017
13. Crystal Structure of the New Investigational Drug Candidate VT-1598 in Complex with Aspergillus fumigatus Sterol 14α-Demethylase Provides Insights into Its Broad-Spectrum Antifungal ActivityAntimicrobial Agents and Chemotherapy · 2017
14. Efficacy of the Investigational Antifungal VT-1161 in Treating Naturally Occurring Coccidioidomycosis in DogsAntimicrobial Agents and Chemotherapy · 2017
15. Structural analyses of Candida albicans sterol 14α-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesisJournal of Biological Chemistry · 2017
16. Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal CompoundsAntimicrobial Agents and Chemotherapy · 2016
17. Activity of VT-1129 againstCryptococcus neoformansclinical isolates with high fluconazole MICsMedical Mycology · 2016
18. The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human EnzymeAntimicrobial Agents and Chemotherapy · 2016
19. The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattiiAntimicrobial Agents and Chemotherapy · 2016
20. Clinical Candidate VT-1161's Antiparasitic EffectIn Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruziAntimicrobial Agents and Chemotherapy · 2015